Tizaro (Tirzepatide) 2.5/5/7.5/10/12.5/15mg/0.5mL Prefilled Syringe | Ziska Bangladesh | GLT

Generic Information: Tizaro (Tirzepatide) — Ziska Pharmaceuticals, Bangladesh

Tizaro is the tirzepatide injection of Ziska Pharmaceuticals Ltd., the Dhaka-based manufacturer that markets this dual-incretin molecule across its export portfolio. The Tizaro range comes as six single-use prefilled syringes of 0.5 mL — Tizaro 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg — mirroring the full six-step titration ladder of the originator's US label. Each syringe is a once-weekly dose and is discarded after a single injection, and the range is supplied as prefilled syringes rather than the multi-dose pens used by some competitors.

What Is Tizaro (Tirzepatide) Used For?

Tizaro is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, and for weight management in obesity or overweight when a weight-related condition is present. The six available strengths map directly onto how tirzepatide is actually dosed in practice: 2.5 mg once weekly for the first four weeks, then 5 mg, then increases of 2.5 mg at least four weeks apart as glucose control tightens, up to a 15 mg weekly maintenance dose. It is intended for patients who have not reached their glucose target on oral agents, and it is explicitly not for type 1 diabetes, nor has it been studied in people with a history of pancreatitis.

How Does Tizaro (Tirzepatide) Work?

The active ingredient is a 39-amino-acid modified peptide carrying a C20 fatty-diacid side chain that binds albumin and stretches the molecule's half-life to once-weekly dosing. It activates two incretin receptors at once — the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor — enhancing first- and second-phase insulin secretion and lowering glucagon only when blood sugar is actually high. The practical result is glucose-dependent glucose control with reduced appetite and slowed gastric emptying, delivered through a prefilled syringe that is refrigerated between doses.

Indications of Tizaro (Bangladesh Label)

The Bangladesh label mirrors the originator's dual scope: type 2 diabetes for glycemic control, and weight management in obesity or overweight with a weight-related comorbidity. It is positioned as a once-weekly option for adults who have not reached target on metformin and other oral therapy, and as a metabolic treatment for obesity that sits alongside structured lifestyle change. As with every tirzepatide product, the label excludes type 1 diabetes and carries the class warnings on medullary thyroid carcinoma and MEN 2.

Dosage and Administration

Tizaro is injected subcutaneously once weekly, at any time of day and with or without food, into the abdomen, thigh or upper arm, rotating the injection site each week. Treatment begins at 2.5 mg weekly for four weeks — a starting dose for tolerability rather than full glucose control — then rises to 5 mg weekly, and can be stepped up by 2.5 mg after at least another four weeks at each stage, reaching 10 mg, 12.5 mg or the 15 mg weekly maximum where more control is needed. Each prefilled syringe holds a single 0.5 mL dose and is used once and discarded. A missed dose is taken as soon as possible within four days; beyond that it is skipped and the next dose is taken on schedule, with at least three days between injections.

Side Effects of Tizaro

The common reactions are gastrointestinal and cluster around dose escalation: nausea, vomiting, diarrhea, constipation, reduced appetite and abdominal pain, most mild to moderate and easing as the body adjusts. The serious cautions are the tirzepatide class warnings — a risk of thyroid C-cell tumors, with medullary thyroid carcinoma and MEN 2 contraindicated, plus pancreatitis, gallbladder disease, hypoglycemia when combined with a sulfonylurea or insulin, and hypersensitivity reactions. Severe, persistent abdominal pain or signs of an allergic reaction warrant immediate medical contact.

Storage Instructions

Keep unopened prefilled syringes refrigerated at 2°C to 8°C in the original carton and protected from light; do not freeze, and discard any syringe that has been frozen. The needle cover contains dry natural rubber (a latex derivative) and may cause allergic reactions in latex-sensitive people. Inspect the solution visually before use — it should be clear and colorless to slightly yellow — and do not use a syringe that has been dropped on a hard surface or shows particulate matter or discoloration.

Why Choose Tizaro from GLT?

Buyers who want a genuine Bangladesh tirzepatide at an accessible price point choose this pack. Ziska's six-strength prefilled-syringe range covers the whole tirzepatide titration ladder — from the 2.5 mg starting dose to the 15 mg ceiling — so a patient can step up within the same brand instead of switching products mid-course, and the single-use format avoids the dosing errors that can arise with multi-dose pens. GLT quotes Tizaro alongside the originator and the other Bangladesh generics (Tixepa, Tirzema) so the landed cost of every option is visible before a decision is made, and sealed stock with pre-shipment photographs and complete export documentation comes standard. A real person answers on WhatsApp +86 15234153837 or at [email protected] for every step between quotation and delivery.

How to Order Tizaro (Tirzepatide)

Message GLT on WhatsApp +86 15234153837 or write to [email protected] with the syringe strength, quantity and destination country. A formal quotation with courier options and payment routes returns, usually within one working day; on confirmation, cold-chain-appropriate packaging and complete export paperwork ship the sealed syringes. Recurring monthly supply can be scheduled in advance so a continuous weekly course never breaks.

FAQ

Is Tizaro a pen or a syringe? It is a prefilled syringe (pre-filled syringe) containing a single 0.5 mL dose — one injection, then discarded. It is not a multi-dose pen.

Does Tizaro come in 10 mg, 12.5 mg or 15 mg? Yes. The full Ziska range is 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg per 0.5 mL syringe — the same six-step ladder as the originator's US label.

Which strength should I start with? Treatment starts at 2.5 mg once weekly for four weeks, then steps up to 5 mg, and by 2.5 mg increments at least four weeks apart as tolerated — the higher strengths serve the later maintenance steps.

Is tirzepatide insulin? No. It is an incretin-based peptide that prompts the body to release its own insulin only when glucose is elevated; it is not a substitute for insulin and is not for type 1 diabetes.

How quickly does weight loss appear? In the registration program, meaningful weight reduction accrued over months of weekly dosing, with the largest effects seen at higher maintenance doses and alongside sustained dietary and activity changes.